Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytokines and Genetic Risk Factors in Anti-VEGF Therapy for Exudative Age-related Macular Degeneration
2006-005684-26Phase 4Completed
- Sponsor
- Department of Ophthalmology, Medical University of Vienna
- Start
- Aug 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of ranibizumab in exudative macular degeneration, cataract and chorioretinal scar (2 arms), sponsored by Department of Ophthalmology, Medical University of Vienna. Primary endpoint: Intraocular VEGF levels at end of treatment. Started Aug 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
exudative macular degenerationcataractchorioretinal scar
Beyond the preview
Go deeper on 2006-005684-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005684-26.